Buto
Private Company
Total funding raised: $5.5M
Overview
Buto Corp is a private, preclinical biotech founded in 2020, targeting the Shc protein pathway to develop anti-fibrotic and anti-inflammatory therapies. The company's platform is based on inhibiting the Shc protein, which is implicated in driving fibrosis and neurodegeneration. Its initial pipeline is focused on lung and liver fibrosis, with exploratory work in Alzheimer's disease. Buto operates as a pre-revenue, research-focused entity, positioning itself in large, underserved markets with significant unmet medical need.
Technology Platform
Small molecule inhibitors targeting the Shc protein pathway to block innate immune system inflammation driving fibrosis and neurodegeneration.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In fibrosis, Buto competes against approved drugs like pirfenidone and nintedanib (IPF) and numerous late-stage NASH programs. In Alzheimer's, it enters a field dominated by amyloid and tau-targeting therapies, with growing interest in neuroinflammation. Buto's differentiation lies in its specific targeting of the Shc pathway, a mechanism not widely pursued by competitors.